What are Mission Vision & Core Values of Jointown Pharmaceutical Group Company?

Jointown's mission emphasizes making healthcare accessible and affordable. This commitment is reflected in its extensive distribution network and focus on cost-effective products. This approach is particularly crucial in the Chinese market, where ensuring widespread access to healthcare is a key priority.

The mission highlights continuous innovation in pharmaceutical research and development. Jointown invests heavily in R&D to develop new drugs and improve existing ones. This focus on innovation allows the Pharmaceutical Company to stay competitive and meet evolving healthcare needs.

Jointown's mission includes a commitment to sustainability and community contribution. This involves implementing environmentally friendly practices and engaging in social responsibility initiatives. This focus is increasingly important for investors and stakeholders.

The mission is strongly customer-centric, emphasizing the provision of high-quality and accessible healthcare solutions. This focus is evident in the company's efforts to streamline operations and enhance efficiency. This approach is critical for long-term success.

Jointown leverages technology for operational efficiency and service delivery. This includes digital pharmaceutical distribution, AI, and cloud computing. These technologies improve customer experience and optimize operations.

Jointown's primary market is China, with an extensive distribution network. The company also has overseas operations in regions like the United States, the Middle East, and Hong Kong. This global presence supports its mission.

The vision explicitly targets the "Global Pharmaceutical and Health industry," signaling Jointown's intention to expand beyond its current domestic market. This global scope suggests a strategic shift towards international influence and a desire to compete on a worldwide scale. The ambition is clear: to become a major player in the global market.

The phrase "best service provider" highlights Jointown's focus on delivering superior services across its diverse business segments. This commitment to excellence is crucial for attracting and retaining customers in a competitive global market. It implies a dedication to quality, efficiency, and customer satisfaction.

This vision is closely aligned with Jointown's strategic goals, which include continuous investment in technology and innovative business models. The company's actions, such as its partnership with HUAWEI CLOUD for digital transformation and the development of AI applications, directly support this vision. These initiatives are critical for achieving the desired level of service excellence.

As the largest private pharmaceutical distribution company in China, Jointown already holds a strong position in its domestic market. This provides a solid foundation for expansion and international growth. In 2023, the company reported revenues of 150.14 billion yuan, demonstrating its significant market presence and financial strength.

While the vision is ambitious, it is grounded in realistic strategic initiatives and market conditions. Jointown's investments in digitalization, its innovative approach to asset management with the China Universal Jointown Pharmaceutical Warehousing and Logistics REIT approved in December 2024, and its strong domestic base suggest a feasible pathway to achieving significant international influence. The company's commitment to innovation and its focus on operational efficiency are key to realizing this vision.

The vision statement reflects Jointown's long-term commitment to the healthcare sector and its ambition to become a leader in the industry. This aspiration is not just about financial success; it's also about making a positive impact on global health and well-being. For a deeper understanding of how Jointown is approaching its growth, consider reading about the Growth Strategy of Jointown Pharmaceutical Group.

The 'New Retail' strategy, centered around the 'Ten-Thousand Store Alliance,' directly addresses the mission of providing accessible healthcare products and expanding market reach. This strategy leverages advanced technologies to create a service system that combines wholesale and retail, BC integration, and online/offline services.

Robust financial performance fuels Jointown's strategic investments and expansion initiatives. The company's financial health supports its mission and vision, enabling further innovation and market penetration.

Jointown's strategic acquisitions and partnerships are carefully chosen to align with its vision of expanding service capabilities and becoming a comprehensive health service platform. These moves demonstrate a proactive approach to growth and diversification.

Leadership plays a crucial role in reinforcing Jointown Pharmaceutical Group's mission and vision through consistent strategic direction. The company's commitment to digitalization, new retail, and expanding service offerings reflects a strong top-down commitment to its guiding principles.

The tangible impact of aligning day-to-day operations and long-term planning with Jointown Pharmaceutical Group's guiding principles is evident in its measurable success metrics. Revenue growth and market position demonstrate the effectiveness of this approach.

In 2024, Jointown's operating income reached 151.81 billion RMB, with a net income attributable to shareholders of 2.51 billion RMB. In April 2025, Jointown Industrial Investment Company planned to invest 0.673 billion yuan to acquire a significant stake in Aoyuan Meigu, demonstrating ongoing investment in growth areas.

Leadership plays a pivotal role in reinforcing Jointown's mission and vision. The company's corporate strategy, spearheaded by Chairman Liu Changyun and General Manager Gong Yihua, is designed to align with its core objectives.

The 'New Retail' strategy, which empowers the 'Ten-Thousand Store Alliance,' is a key initiative. This initiative directly supports the goal of expanding service to C-end customers and enhancing their overall experience, leveraging advanced technologies.

Jointown Pharmaceutical Group communicates its mission and vision through publicly available corporate information and sustainability reports. This transparency helps build trust with stakeholders and demonstrates the company's commitment to ethical practices.

Jointown's ESG practices, reflected in its upgraded MSCI ESG rating to 'A' in 2024, highlight its commitment to responsible business operations. The company actively engages in programs to build a sustainable supply chain and reduce waste emissions, showcasing its dedication to environmental and social responsibility.